DNA-PKcs promuove la resistenza terapeutica e la recidiva metastatica nel neuroblastoma.

PURPOSE: High-risk neuroblastoma presents a serious clinical challenge with survival rates below 50%. Disease relapse most commonly occurs at distant metastatic sites and remains the primary driver of poor outcomes, emphasizing the need for therapies to target drivers of relapse. EXPERIMENTAL DESIGN: This study identified DNA-PKcs as a critical determinant of poor survival and metastatic relapse in neuroblastoma patients. We evaluated which therapeutic modality-chemotherapy or radiotherapy-when combined with DNA-PKcs inhibition, more effectively reduces metastatic burden and prevents recurrence. RESULTS: Colony-forming assays revealed that established neuroblastoma colonies resist doxorubi